Sanghuang and Cancer: Research on Phellinus igniarius

Sanghuang Cancer Research

2 chemotherapy drugs Phellinus synergized with in cell culture

In separate studies, Phellinus linteus extract enhanced the anti-cancer activity of both 5-fluorouracil (in breast cancer) and cetuximab (in colon cancer), suggesting potential as a chemotherapy adjuvant.

Lee et al., 2015; Park et al., 2017

6 cancers

prostate, breast, colon, liver, melanoma, and lung: all studied with Phellinus species in published research

dual apoptosis

both intrinsic (mitochondrial) and extrinsic (death receptor) pathways activated in prostate cancer

1 human RCT

immunity improvement trial, the only clinical data in the entire Phellinus cancer research program

Lee et al., 2015; Park et al., 2017

View as image ↗

A quick taxonomy note before the research: the title says "Phellinus igniarius" because that name appears in older literature and product labeling, but the majority of cancer studies reviewed here used Phellinus linteus, the species cultivated in Korea and sold as Mesima in supplement form. In China, the name "sanghuang" typically refers to Sanghuangporus sanghuang (formerly classified under Phellinus). These are related but distinct. For the taxonomy breakdown in full, see Sanghuang vs. Meshima: Different Species, Different Research.

What follows is what the published research has actually found, organized by cancer type. The findings span from cell culture to mouse models to one human clinical trial. The two chemotherapy synergy studies are the most clinically interesting results and the ones most absent from general-audience coverage.

For a broader introduction to the species, see What Is Sanghuang? Korea's Cancer-Fighting Mushroom.

The Research by Cancer Type

The Research, Mapped by Cancer Type

How Far Each Cancer Line of Evidence Actually Goes

Phellinus has been tested against six tumor types — unusual breadth for a specialty mushroom. But breadth is not depth. Reading the rows left to right shows where each line of evidence stops: prostate and lung reach animal models; breast, colon, liver, and melanoma remain in cell culture. No cancer row reaches a human endpoint. The one human trial in the entire program measured immune parameters, not cancer outcomes — shown separately below the grid for exactly that reason.

The one human trial

Ku 2022 — a CONSORT randomized, double-blind, placebo-controlled trial [8]

Phellinus linteus extract significantly improved immune parameters versus placebo in humans. It is the only clinical evidence in the Phellinus cancer research program — and it measured immunity, not tumor outcomes. That is why it sits outside the grid above rather than filling a “Human” column for any cancer type.

Polysaccharides & protein-bound polysaccharides

Immune activation, cell-cycle arrest, chemotherapy sensitization. Refs [1][3][5][6][8][10].

Hispolon (direct-cytotoxic polyphenol)

Anti-proliferative and anti-metastatic activity via MDM2/ERK and MMP inhibition. Refs [9][11].

Every filled dot marks preclinical evidence only — cell culture or animal models. Cell-culture concentrations and mouse doses are not directly translatable to oral supplement doses in people, and no human trial has measured a cancer outcome from Phellinus. This map shows the shape of the evidence, not a claim that sanghuang treats cancer.

Evidence synthesis; rows from refs [1]–[11] (see references)

Prostate Cancer: Two Studies, Two Stages of Disease

The prostate cancer evidence for Phellinus is among the strongest in the literature, covering both early-stage and advanced (hormone-refractory) disease.

Zhu and colleagues (British Journal of Cancer, 2007) tested P. linteus extract against two prostate cancer cell lines: LNCaP (hormone-responsive) and DU-145 (hormone-refractory).^[1] The extract induced apoptosis through two independent pathways simultaneously. The intrinsic pathway involves mitochondria signaling to destroy the cell from within; the extrinsic pathway involves death receptors on the cell surface being activated from outside. Most apoptosis-inducing compounds work through one or the other. The P. linteus extract activated both.

This dual-pathway mechanism has a practical implication: cancer cells can sometimes develop resistance to one apoptosis route, especially under treatment pressure. A compound that requires failure of both routes before losing effectiveness is potentially more difficult for cancer cells to evade. This is speculative at the cell culture level, but it is the mechanistic basis for why researchers found the finding significant.

Tsuji and colleagues (2010) extended the prostate cancer work into animal models, testing P. linteus extract in athymic (immune-deficient) mice bearing hormone-refractory prostate cancer xenografts.^[2] The extract sensitized the advanced cancer cells to apoptosis. Hormone-refractory prostate cancer is notoriously difficult to treat; the cells have already survived the pressure of androgen deprivation therapy and tend to be resistant to many agents. The finding that P. linteus extract could sensitize these cells in a whole-animal model is one of the more clinically suggestive data points in the Phellinus cancer literature.

Breast Cancer: Three Mechanisms and a Chemotherapy Synergy

Two breast cancer studies cover different aspects of the disease process and arrive at complementary findings.

Sliva and colleagues (British Journal of Cancer, 2008) found that P. linteus extract suppressed breast cancer cell growth, angiogenesis, and invasive behavior through inhibition of AKT signaling.^[3] AKT (also called Protein Kinase B) is a central signaling protein that promotes cell survival, proliferation, and the formation of new blood vessels. Cancer cells frequently rely on overactive AKT to grow and spread. Suppressing it simultaneously reduced three separate aspects of the disease: the cancer cells divided less frequently, formed fewer new blood vessels to sustain themselves, and became less capable of invading surrounding tissue.

Lee and colleagues (Nutrition and Cancer, 2015) took a different angle, asking whether P. linteus extract could enhance the effect of an existing chemotherapy drug.^[4] They tested it alongside 5-fluorouracil (5-FU), one of the most widely used chemotherapy agents for breast cancer and other solid tumors. The combination produced greater cancer cell inhibition than either treatment alone. The mechanism involved autophagy: the P. linteus extract induced autophagy (cellular self-digestion) in cancer cells, which appeared to sensitize them to the cytotoxic effects of 5-FU. The research suggests a potential role not as a replacement for chemotherapy but as a sensitizing agent that could improve chemotherapy efficacy.

Colon Cancer: Cell Cycle Arrest and Cetuximab Enhancement

Two separate colon cancer studies cover different mechanisms and suggest a potential role as a chemotherapy adjuvant.

Li and colleagues (Cancer Letters, 2004) tested protein-bound polysaccharide from P. linteus against SW480 human colon cancer cells.^[5] The extract induced G2/M cell cycle arrest, a phase where cells stop dividing and can undergo programmed death. The mechanism involved activation of caspase-3 and caspase-8, enzymes that execute the apoptosis program. G2/M arrest is a commonly studied target in anti-cancer drug development because blocking cancer cells at this checkpoint prevents them from completing cell division.

Park and colleagues (International Journal of Molecular Sciences, 2017) produced one of the more unusual findings in the sanghuang literature: P. linteus grown on germinated brown rice substrate enhanced KRAS-mutated colon cancer cell sensitivity to cetuximab, a monoclonal antibody therapy that targets the EGFR receptor on colon cancer cells.^[6] The mechanism involved downregulation of amphiregulin and ErbB3, two proteins that allow cancer cells to bypass the EGFR blockade that cetuximab creates. The substrate detail is noteworthy: the compound profile of P. linteus changes depending on what substrate the mushroom is grown on, and the germinated brown rice substrate appears to produce bioactive compounds with this cetuximab-sensitizing activity. KRAS-mutated colon cancers are normally poor responders to cetuximab, which makes the restored sensitivity in this cell model especially notable.

Chemotherapy Synergy

Park et al. (2017) · International Journal of Molecular Sciences

Population

KRAS-mutated human colon cancer cell lines (in vitro)

Intervention

P. linteus grown on germinated brown rice substrate, combined with cetuximab (an anti-EGFR antibody)

Comparator

Cetuximab alone

Finding

The extract downregulated amphiregulin and ErbB3 — two proteins cancer cells use to bypass EGFR blockade — restoring sensitivity to cetuximab in cells that are normally poor responders.

preliminary Cell-culture only; no animal or human study has tested the cetuximab combination.

Park et al., 2017 [6]

Lung Cancer: The 2023 Sanghuangporus Study

A 2023 study by Wang and colleagues extended the cancer research to the Chinese species classification, using Sanghuangporus sanghuang extract (the modern genus name for Chinese sanghuang) in lung cancer models.^[7]

The findings: the extract inhibited lung cancer cell proliferation and invasion, in both cell culture and a mouse model. This study is notable for two reasons. First, it adds lung cancer to the evidence portfolio and provides in vivo (animal) confirmation rather than cell-culture data alone, placing lung alongside prostate as one of the two cancer types with animal-model evidence. Second, it uses the modern Sanghuangporus taxonomy, clarifying that the Chinese species (not only the Korean P. linteus) has anti-cancer activity.

The downstream molecular mechanism was not fully characterized in the study summary available, placing the mechanistic detail in the exploratory category even though the anti-tumor effect itself was shown in an animal model. Nonetheless, it represents the most recent addition to the Phellinus cancer research program and suggests the anti-cancer activity extends to the Chinese species.

Liver, Melanoma, and the Hispolon Compound Class

The prostate, breast, and colon findings above come largely from Phellinus polysaccharides. A second compound class — hispolon, a direct-cytotoxic polyphenol — accounts for much of the remaining cancer research and extends it to two more tumor types.

Huang and colleagues (Journal of Agricultural and Food Chemistry, 2010) reported that hispolon suppressed metastasis in SK-Hep1 human hepatoma (liver cancer) cells by inhibiting matrix metalloproteinases (MMP-2 and MMP-9), the enzymes cancer cells use to dissolve surrounding tissue and spread.^[9] Blocking these enzymes reduced the cells' invasive and migratory behavior in culture.

Han and colleagues (International Immunopharmacology, 2006) had earlier shown a parallel anti-metastatic effect in melanoma: an acidic polysaccharide from P. linteus inhibited melanoma cell metastasis by blocking cell adhesion and invasion.^[10] Together, the liver and melanoma work establishes anti-metastasis — not just anti-proliferation — as a recurring theme across Phellinus compounds.

The hispolon mechanism itself was characterized by Lu and colleagues (Food and Chemical Toxicology, 2009), who found that hispolon has antiproliferative effects in breast and bladder cancer cells through MDM2-recruited ERK1/2 activity — a pathway that pushes cells toward death even when their p53 "brake" is partly disabled.^[11] This is the compound-level basis for hispolon's direct cytotoxic activity, distinct from the immune-activating role of the polysaccharides. For the deeper compound-level detail, see Sanghuang: Korea and China's Prized Anti-Cancer Mushroom and Its Hispidin Content.

The One Human Study: Immunity, Not Cancer Directly

Every cancer study described above was conducted in cell cultures or animal models. The only human clinical trial in the Phellinus cancer research program did not test cancer outcomes directly.

Ku and colleagues (Medicine, 2022) conducted a CONSORT-standards randomized double-blind placebo-controlled trial of P. linteus extract in humans, measuring immune parameters as the primary outcome.^[8] The extract significantly improved immune parameters compared to placebo. CONSORT standards indicate the trial met rigorous design requirements for bias control. The finding establishes that P. linteus extract produces measurable immune modulation in humans, a clinically important finding even without direct cancer outcome data, because immune function is foundational to cancer surveillance and response to treatment.

The absence of direct cancer outcome trials is the single largest gap between the Phellinus cancer research program and clinical translation. Decades of cell culture and animal data have established compelling mechanisms. The step to human trials that test whether those mechanisms translate to clinical benefit has not been taken for cancer outcomes specifically.

Evidence Review

1. Cell studiescompleted

   Prostate, breast, colon, liver, melanoma, and lung cancer lines — multiple mechanisms

2. Animal studiescompleted

   Advanced prostate cancer sensitization in mice (Tsuji 2010); lung tumor inhibition in mice (Wang 2023)

3. Case reportsmissing

   No published human cancer case series for sanghuang

4. Human trialcurrent

   One CONSORT RCT (Ku 2022) — but it measured immune parameters, not cancer outcomes

5. Cancer-outcome RCTmissing

   No trial testing tumor response or survival has been registered

6. Meta-analysismissing

Cancer findings top out at animal models. The one human trial measured immune function, not tumor outcomes. The jump to cancer-endpoint trials — the step that would tell us whether any of this helps patients — has not been made.

Zhu 2007 [1]; Tsuji 2010 [2]; Wang 2023 [7]; Ku 2022 [8]

What These Studies Collectively Suggest

The breadth of the Phellinus cancer research is unusual among specialty mushrooms. Most mushrooms have one or two cancer studies in one or two cancer types. Phellinus linteus has been tested against prostate, breast, colon, liver, melanoma, and lung cancers across more than a decade of research, with two distinct compound classes (polysaccharides and hispolon) targeting different mechanisms.

The most clinically translatable findings are the chemotherapy synergy studies. The observation that P. linteus extract enhances both 5-FU (a widely used chemotherapy) and cetuximab (a targeted antibody therapy) in cell models is the kind of finding that typically informs phase 1 combination therapy trials. No such trials have been registered or published for sanghuang at the time of writing.

The standard caveats for this entire evidence base are important: cell culture studies demonstrate mechanistic potential, not clinical efficacy. Cancer cells in a dish behave differently from cancer cells in a living human body with immune function, blood supply, and tumor microenvironment. Animal studies narrow the gap somewhat: the Tsuji 2010 advanced prostate cancer sensitization in mice, and the Wang 2023 lung tumor inhibition in mice, are meaningfully closer to clinical relevance than cell culture alone. But none of this is human cancer outcome data.

Using sanghuang alongside cancer treatment

Moderate

Preclinical synergy is not clearance to combine sanghuang with chemotherapy

Concern

The 5-FU and cetuximab synergy findings are cell-culture results. Mushroom extracts can also affect drug-metabolizing enzymes and, in theory, alter how much chemotherapy reaches the tumor — up or down. None of this has been measured in people.

What the research says

No human trial has tested sanghuang as a chemotherapy adjuvant. Any combined use should be decided and monitored by the treating oncology team, not self-directed based on laboratory findings.

Particularly relevant for: Anyone in active cancer treatment or on targeted or antibody therapies

What to do

Tell your oncology team about any mushroom supplement before starting or continuing it during treatment. This article is educational and is not medical advice.

Lee et al., 2015 [4]; Park et al., 2017 [6]

For the compound-level detail on hispidin and hispolon, the unique polyphenols driving much of sanghuang's direct anti-cancer activity, see Sanghuang: Korea and China's Prized Anti-Cancer Mushroom and Its Hispidin Content. For a comparison of sanghuang with meshima, which shares species identity but different cultural context and research framing, see Sanghuang vs. Meshima: Different Species, Different Research.

The Bottom Line

Phellinus linteus has cancer research across six tumor types: prostate (dual apoptosis pathways; advanced cancer sensitization in mice), breast (AKT inhibition + triple mechanism; 5-FU synergy), colon (G2/M arrest; cetuximab synergy), liver (hispolon-mediated metastasis suppression via MMP inhibition), melanoma (metastasis blocked through adhesion/invasion inhibition), and lung (2023 Sanghuangporus data with animal-model confirmation). The chemotherapy synergy studies are the most clinically interesting findings. The only human trial tested immunity, not cancer outcomes. The gap between the preclinical evidence and clinical validation is the defining characteristic of the entire sanghuang cancer research program.

Frequently Asked Questions

What cancers has Phellinus igniarius been studied for?

Research on Phellinus linteus (the primary species behind most sanghuang cancer studies) covers prostate cancer (Zhu 2007, Tsuji 2010), breast cancer (Sliva 2008, Lee 2015), colon cancer (Li 2004, Park 2017), liver cancer (Huang 2010, hispolon), and melanoma (Han 2006). A 2023 study using the Chinese species Sanghuangporus sanghuang (Wang 2023) found anti-proliferative and anti-invasive activity in lung cancer models. All cancer studies are preclinical (in vitro or animal models); the only human trial tested immune parameters, not cancer outcomes.

How does sanghuang mushroom fight cancer?

Phellinus species fight cancer through two distinct compound classes: polysaccharides and protein-bound polysaccharides activate immune cells (NK cells, T cells) and cause cell cycle arrest (G2/M phase) in cancer cells; hispolon (a direct cytotoxic compound) inhibits cancer cell proliferation through the MDM2/ERK pathway and suppresses metastasis by blocking the matrix metalloproteinases (MMP-2/9) that allow cancer cells to invade surrounding tissue. Both compound classes have been identified in multiple cancer cell studies.

Does sanghuang mushroom help with prostate cancer?

Phellinus linteus extract has been studied in prostate cancer cell lines and in mice with advanced prostate cancer. Zhu and colleagues (2007) found the extract induced apoptosis through both intrinsic and extrinsic pathways in prostate cancer cells. Tsuji and colleagues (2010) showed the extract sensitized hormone-refractory prostate cancer cells to apoptosis in an animal model. There are no human clinical trials of sanghuang for prostate cancer; these findings are preclinical.

Can sanghuang mushroom be used with chemotherapy?

Two cell culture studies found that Phellinus linteus extract enhanced chemotherapy effects: Lee and colleagues (2015) found synergy with 5-fluorouracil in breast cancer cells, and Park and colleagues (2017) found that P. linteus grown on germinated brown rice enhanced cetuximab sensitivity in KRAS-mutated colon cancer cells. These are laboratory findings, not human trials. No clinical trial has tested sanghuang as a chemotherapy adjuvant in cancer patients. Any use alongside conventional cancer treatment would require medical supervision.

What is the evidence for sanghuang against breast cancer?

Two published studies cover Phellinus linteus and breast cancer. Sliva and colleagues (British Journal of Cancer, 2008) found the extract suppressed breast cancer cell growth, blocked angiogenesis, and reduced invasiveness through AKT signaling inhibition. Lee and colleagues (2015) found the extract synergized with 5-fluorouracil, enhancing chemotherapy efficacy through autophagy induction. Both studies are in vitro (cell culture). No human clinical trial has tested sanghuang specifically for breast cancer outcomes.

How does Phellinus linteus help cancer?

Phellinus linteus appears to address cancer through multiple mechanisms operating in parallel: immune activation (stimulating NK cells and T cells to target cancer cells), direct apoptosis induction in cancer cells via both intrinsic and extrinsic pathways, cell cycle arrest (blocking cancer cell division at the G2/M checkpoint), anti-angiogenesis (reducing blood vessel formation that feeds tumors), and anti-metastasis (inhibiting the enzymes and proteins that allow cancer cells to invade tissue). Ku and colleagues' 2022 human RCT confirmed immunomodulatory activity in people, though this trial did not measure cancer outcomes specifically.

Sources & References

1. 1RTHM-00240·Zhu, T et al. (2007). “Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells..” British journal of cancer.Study breakdown →PubMed →↩
2. 2RTHM-00367·Tsuji, Takanori et al. (2010). “Phellinus linteus extract sensitizes advanced prostate cancer cells to apoptosis in athymic nude mice..” PloS one.Study breakdown →PubMed →↩
3. 3RTHM-00271·Sliva, D et al. (2008). “Phellinus linteus Extract in Breast-Cancer Cell Models: What This 2008 Study Actually Found.” British journal of cancer.Study breakdown →PubMed →↩
4. 4RTHM-00710·Lee, Wen-Ying et al. (2015). “Phellinus linteus extract induces autophagy and synergizes with 5-fluorouracil to inhibit breast cancer cell growth..” Nutrition and cancer.Study breakdown →PubMed →↩
5. 5RTHM-00140·Li, Ge et al. (2004). “Protein-bound polysaccharide from Phellinus linteus induces G2/M phase arrest and apoptosis in SW480 human colon cancer cells..” Cancer letters.Study breakdown →PubMed →↩
6. 6RTHM-00904·Park, Hye-Jin et al. (2017). “Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer..” International journal of molecular sciences.Study breakdown →PubMed →↩
7. 7RTHM-01817·Wang, Weike et al. (2023). “Sanghuangporus sanghuang extract inhibits the proliferation and invasion of lung cancer cells in vitro and in vivo..” Nutrition research and practice.Study breakdown →PubMed →↩
8. 8RTHM-01556·Ku, Yong Ho et al. (2022). “Effects of Phellinus linteus extract on immunity improvement: A CONSORT-randomized, double-blinded, placebo-controlled trial..” Medicine.Study breakdown →PubMed →↩
9. 9RTHM-00344·Huang, Guan-Jhong et al. (2010). “Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
10. 10RTHM-00185·Han, Sang-Bae et al. (2006). “Acidic polysaccharide from Phellinus linteus inhibits melanoma cell metastasis by blocking cell adhesion and invasion..” International immunopharmacology.Study breakdown →PubMed →↩
11. 11RTHM-00306·Lu, Te-Ling et al. (2009). “Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells..” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.Study breakdown →PubMed →↩